Navigation Links
EUCODIS Bioscience Launches Lipase Portfolio
Date:9/21/2009

VIENNA, Austria, September 21 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has launched the first enzymes of its lipase portfolio. EUCODIS Bioscience currently offers 12 lipases that have been selected to cover a broad range of potential industrial applications.

Lipases are an enzyme family that is widely used across the chemical industry, including the pharmaceutical, cosmetics, textiles, and food and feed industries. EUCODIS Bioscience offers customers to supply lipases of interest up to the kilogram scale. The Company can also customize promising lipases to properties specified by the customer, using its proven in-vivo recombination technology.

"With the launch of our lipases portfolio we enter a market of USD 300 million," said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "In recent years our organization has accumulated a unique expertise in the development, customization, and manufacturing of industrial lipases. Our customers can select from our portfolio of currently 12 lipases which include both enzymes designed for well-established uses as well as those with exciting novel properties. Going forward we plan to expand our lipase platform and to leverage the industrial expertise we can offer in this area."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visithttp://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
   http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net



'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
2. EUCODIS Bioscience Signs Research Agreement With Genencor
3. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
4. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
5. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
7. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
8. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
9. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
10. Neurocrine Biosciences Secures Committed Equity Financing Facility
11. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... During the course of ... testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn the medical ... D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, will be ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 ... extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific ... offer NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As part of the ... explore the laboratory testing for DIC in order to illuminate this clinical problem for ... occur in hospitalized patients resulting in a high degree of morbidity and mortality. DIC ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
Breaking Biology News(10 mins):